Physician profile
Gregory Sullivan Mcgee
NPI 1831197672
$954.53
in general payments reported to CMS, 2019-2025
14 companies · $79.12 in 2025
The $79.12 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $480 · 2021: $185 · 2022: $33.81 · 2023: $95.86 · 2024: $80.37 · 2025: $79.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $199.07 | 2020-2021 | |
| Lemaitre Vascular, INC. | $156.00 | 2020-2022 | |
| Getinge USA Sales, LLC | $143.52 | 2020 | |
| Penumbra, INC. | $125.28 | 2021 | |
| W. L. Gore & Associates, INC. | $78.73 | 2024-2025 | Viabahn Endoprosthesis With Propaten Bioactive Surface, Gore Propaten Vascular Graft |
| Boston Scientific Corporation | $57.73 | 2023 | |
| Baxter Healthcare | $43.60 | 2021 | |
| Integra Lifesciences Corporation | $36.24 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $25.06 | 2024 | Renasys Touch, Pico 7 |
| Convatec INC. | $24.05 | 2023 | |
| Cardiovascular Systems INC. | $19.48 | 2022 | |
| Kerecis Limited | $19.46 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sanara Medtech INC. | $14.08 | 2023 | Celleraterx |
| Novo Nordisk INC | $12.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.